Literature DB >> 6602022

Further studies of the C3g component of the alpha 2D fragment of human C3.

H Chaplin, M C Monroe, P J Lachmann.   

Abstract

Recent studies employing sheep red cells, rabbit anti-sheep cell IgM, guinea-pig R3 reagent and purified human C3, factor I, factor H and human serum have led to the discovery of a new C3b breakdown product antigen, C3g, which is present on the alpha 2D fragment of C3 but is removed by trypsinization. The present studies were undertaken to confirm the above findings in entirely human red cell and serum systems, including studies on cells from nine patients with a variety of complement-mediated autoimmune haemolytic anemias. The results confirm the recently reported findings in every respect. The presence of both C3d and C3g on all patient's red cells so far tested supports the concept that red cells coated by C3d alone are likely to be a laboratory artefact and that the alpha 2D fragment (C3d,g) is the natural end product of cell bound C3b breakdown in vivo.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6602022      PMCID: PMC1536777     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  11 in total

1.  Purification and use of the C3d subunit C3.

Authors:  J A Moore; J M Michael; H Chaplin
Journal:  Transfusion       Date:  1976 May-Jun       Impact factor: 3.157

2.  Anti-C3d antiglobulin reagents. I. Characteristics of the anti-C3c and anti-C3d responses during hyperimmunization in rabbits.

Authors:  J A Moore; H Chaplin
Journal:  Transfusion       Date:  1974 Sep-Oct       Impact factor: 3.157

3.  Antigenic determinants of human beta-1c and beta-1g-globulins.

Authors:  C West; N C Davis; J Forristal; J Herbst; R Spitzer
Journal:  J Immunol       Date:  1966-04       Impact factor: 5.422

4.  Preparation of red cells coated with C4 and C3 subcomponents and production of anti-C4d and anti-C3d.

Authors:  J Freedman; P L Mollison
Journal:  Vox Sang       Date:  1976-10       Impact factor: 2.144

5.  Quantitation of red blood cell-bound C3d in normal subjects and random hospitalized patients.

Authors:  H Chaplin; M Nasongkla; M C Monroe
Journal:  Br J Haematol       Date:  1981-05       Impact factor: 6.998

6.  Characterization of red blood cells strongly coated in vitro by C3 via the alternative pathway.

Authors:  H Chaplin; J Freedman; A Massey; M C Monroe
Journal:  Transfusion       Date:  1980 May-Jun       Impact factor: 3.157

7.  A simple method for preparation of C3c fragment from trypsinized serum-reacted zymosan.

Authors:  H Chaplin; N L Hoffmann; M C Monroe
Journal:  Transfusion       Date:  1980 May-Jun       Impact factor: 3.157

8.  Three rat monoclonal antibodies to human C3.

Authors:  P J Lachmann; R G Oldroyd; C Milstein; B W Wright
Journal:  Immunology       Date:  1980-11       Impact factor: 7.397

9.  Breakdown of C3 after complement activation. Identification of a new fragment C3g, using monoclonal antibodies.

Authors:  P J Lachmann; M K Pangburn; R G Oldroyd
Journal:  J Exp Med       Date:  1982-07-01       Impact factor: 14.307

10.  Isolation of a fragment (C3a) of the third component of human complement containing anaphylatoxin and chemotactic activity and description of an anaphylatoxin inactivator of human serum.

Authors:  V A Bokisch; H J Müller-Eberhard; C G Cochrane
Journal:  J Exp Med       Date:  1969-05-01       Impact factor: 14.307

View more
  6 in total

Review 1.  CR1 and the cell membrane proteins that bind C3 and C4. A basic and clinical review.

Authors:  J G Wilson; N A Andriopoulos; D T Fearon
Journal:  Immunol Res       Date:  1987       Impact factor: 2.829

Review 2.  The role of complement in immune clearance of blood cells.

Authors:  U E Nydegger; M D Kazatchkine
Journal:  Springer Semin Immunopathol       Date:  1983

3.  Monoclonal antibodies against complement 3 neoantigens for detection of immune complexes and complement activation. Relationship between immune complex levels, state of C3, and numbers of receptors for C3b.

Authors:  M T Aguado; J D Lambris; G C Tsokos; R Burger; D Bitter-Suermann; J D Tamerius; F J Dixon; A N Theofilopoulos
Journal:  J Clin Invest       Date:  1985-10       Impact factor: 14.808

4.  Dynamics of interaction between complement-fixing antibody/dsDNA immune complexes and erythrocytes. In vitro studies and potential general applications to clinical immune complex testing.

Authors:  R P Taylor; C Horgan; M Hooper; J Burge
Journal:  J Clin Invest       Date:  1985-01       Impact factor: 14.808

5.  The quantification of erythrocyte antigen sites with monoclonal antibodies.

Authors:  A H Merry; E E Thomson; D J Anstee; F Stratton
Journal:  Immunology       Date:  1984-04       Impact factor: 7.397

6.  Identification of the membrane receptor for the complement fragment C3d by means of a monoclonal antibody.

Authors:  K Iida; L Nadler; V Nussenzweig
Journal:  J Exp Med       Date:  1983-10-01       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.